![Figure 2: Analysis of immune cell subsets during neoadjuvant therapy.](https://www.oncotarget.net/wp-content/uploads/2024/03/Screen-Shot-2024-03-27-at-9.55.15-AM-300x181.png)
Durvalumab and Tremelimumab Before Surgery in Patients With HR+/HER2-negative Breast Cancer
March 27, 2024
this trial was stopped early after 3 of the first 8 enrolled patients experienced immunotherapy-related toxicity or suspected disease progression [...]”BUFFALO, NY- March 27, 2024 – A new research paper was... read more